Nav: Home

Sleep hormone helps breast cancer drug kill more cancer cells

June 14, 2016

Amsterdam, June 14, 2016 - Tiny bubbles filled with the sleep hormone melatonin can make breast cancer treatment more effective, which means people need a lower dose, giving them less severe side effects. In a new study published in Colloids and Surfaces B: Biointerfaces, researchers show that the bubbles, called nanostructured lipid carriers (NLCs), made tamoxifen stronger and help it kill cancer cells.

The authors of the study, from Tabriz University of Medical Sciences in Iran, say using NLCs packed with melatonin could also help avoid the cancer cells growing resistant to the treatment, so it will remain effective.

According to the Centers for Disease Control and Prevention (CDC), breast cancer is the most common cancer in women; more than 224,000 people were diagnosed with breast cancer in 2012 in the US alone. The leading medication used to treat breast cancer is a drug called tamoxifen, which stops breast cells from growing.

Despite its popularity, tamoxifen has some serious side effects. It can increase the risk of uterine cancer, stroke, pulmonary embolism and can cause vision problems. More common side effects include irregular menstruation, hot flushes and weight loss.

There is also the developing problem of chemoresistance: cancer cells can get used to a treatment like tamoxifen and become resistant to it, which means it will become less effective and ultimately stop working altogether.

Researchers have been working on ways to address these two problems: side effects and chemoresistance. Previous research has shown that the sleep hormone melatonin can help cancer cells die, so the researchers behind the new study wanted to see if they could use it to help tamoxifen kill cells more effectively.

"We tried to solve both issues by putting melatonin into nanostructures so they can help the chemotherapeutic agent kill more cells," said corresponding author Dr. Nasser Samadi, from Tabriz University of Medical Sciences. "By doing this, you can decrease the dose of tamoxifen needed, reducing the severity of the side effects."

Melatonin is a naturally occurring hormone produced in the body. We need it for many things, like sleep and the growth and development of different tissues. It also helps cancer cells die, but because melatonin is not very stable, it breaks down quickly in the body so it needs to be re-injected or taken again every few hours.

Dr. Samadi and the team tested the effectiveness of melatonin as an adjuvant to tamoxifen. To overcome its short survival time, they developed tiny bubbles called nanostructured lipid carriers (NLCs) that can release melatonin slowly over a period of time. Essentially, this means the treatment can kill the cancer cells continuously, without needing to take new doses of melatonin.

Testing the structures on cells in the lab, the researchers found that melatonin-loaded NLCs inhibited the growth of breast cancer cells more effectively than melatonin alone. They also tested the empty NLCs and found that they did not kill the breast cancer cells without the melatonin, but they were not toxic to surrounding tissue - a promising finding, said Dr. Samadi:

"Lots of nanostructures these days are toxic to the body or to other cells, but we found no significant toxicity in the empty NLCs. The characteristics are very suitable for applying to these kinds of treatments.

This research is still at an early stage; the team plans to test their NLCs on other cancer cells and treatments before moving to animal models and, eventually, clinical trials.
-end-
This research was funded by the Drug Applied Research Center, Tabriz University of Medical Sciences.

Notes for editors

The article is "Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment" by Mehdi Sabzichi, Nasser Samadi, Jamal Mohammadian, Hamed Hamishehkar, Maryam Akbarzadeh and Ommoleila Molavi (doi: 10.1016/j.colsurfb.2016.04.042). It appears in Colloids and Surfaces B: Biointerfaces, Volume 145 (2016), published by Elsevier.

A copy of the paper is available to credentialed journalists upon request, contact Elsevier's Newsroom at newsroom@elsevier.com or +31 204 852 492.

About Colloids and Surfaces B: Biointerfaces

Colloids and Surfaces B: Biointerfaces is an international journal devoted to fundamental and applied research on colloid and interfacial phenomena in relation to biological systems. It is particularly relevant to the medical, pharmaceutical, biotechnological, food and cosmetic fields. Topics covered in the journal include drug delivery and controlled release, biofilm formation, bio-imaging materials and the self-assembly of molecules.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. http://www.elsevier.com

Media contact

Aileen Christensen
Elsevier
+31 204 852 053
a.christensen@elsevier.com

Elsevier

Related Breast Cancer Articles:

Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
Surgery to remove unaffected breast in early breast cancer increases
The proportion of women in the United States undergoing surgery for early-stage breast cancer who have preventive mastectomy to remove the unaffected breast increased significantly in recent years, particularly among younger women, and varied substantially across states.
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Some early breast cancer patients benefit more from breast conservation than from mastectomy
Breast conserving therapy (BCT) is better than mastectomy for patients with some types of early breast cancer, according to results from the largest study to date, presented at ECC2017.
One-third of breast cancer patients not getting appropriate breast imaging follow-up exam
An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren't receiving this follow-up exam, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.
Low breast density worsens prognosis in breast cancer
Even though dense breast tissue is a risk factor for breast cancer, very low mammographic breast density is associated with a worse prognosis in breast cancer patients.
Is breast conserving therapy or mastectomy better for early breast cancer?
Young women with early breast cancer face a difficult choice about whether to opt for a mastectomy or breast conserving therapy (BCT).
Breast density and outcomes of supplemental breast cancer screening
In a study appearing in the April 26 issue of JAMA, Elizabeth A.
Full dose radiotherapy to whole breast may not be needed in early breast cancer
Five years after breast-conserving surgery, radiotherapy focused around the tumor bed is as good at preventing recurrence as irradiating the whole breast, with fewer side effects, researchers from the UK have found in the large IMPORT LOW trial.

Related Breast Cancer Reading:

Chicken Soup for the Soul: Hope & Healing for Your Breast Cancer Journey: Surviving and Thriving During and After Your Diagnosis and Treatment
by Dr. Julie Silver (Author)

Dear Friend: Letters of Encouragement, Humor, and Love for Women with Breast Cancer
by Gina L Mulligan (Author)

Dr. Susan Love's Breast Book (A Merloyd Lawrence Book)
by Susan M. Love (Author), Karen Lindsey (Contributor), Elizabeth Love (Contributor)

The Breast Cancer Survival Manual, Sixth Edition: A Step-by-Step Guide for Women with Newly Diagnosed Breast Cancer
by John Link M.D. (Author), James Waisman M.D. (Author), Nancy Link R.N. (Author)

The Whole-Food Guide for Breast Cancer Survivors: A Nutritional Approach to Preventing Recurrence (The New Harbinger Whole-Body Healing Series)
by Edward Bauman MEd PhD (Author), Helayne Waldman MS EdD (Author), Donald I. Abrams MD (Foreword)

Heal Breast Cancer Naturally: 7 Essential Steps to Beating Breast Cancer
by Dr. Veronique Desaulniers (Author)

Breast Cancer Smoothies: 100 Delicious, Research-Based Recipes for Prevention and Recovery
by Daniella Chace (Author)

Just Get Me Through This! - Revised and Updated: A Practical Guide to Coping with Breast Cancer
by Deborah A. Cohen (Author), Robert M. Gelfand M.D. (Author)

Breast Cancer Husband: How to Help Your Wife (and Yourself) during Diagnosis, Treatment and Beyond
by Marc Silver (Author), Frederick Smith (Foreword)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Where Joy Hides
When we focus so much on achievement and success, it's easy to lose sight of joy. This hour, TED speakers search for joy in unexpected places, and explain why it's crucial to a fulfilling life. Speakers include inventor Simone Giertz, designer Ingrid Fetell Lee, journalist David Baron, and musician Meklit Hadero.
Now Playing: Science for the People

#500 500th Episode
This week we turn 500! To celebrate, we're taking the opportunity to go off format, talk about the journey through 500 episodes, and answer questions from our lovely listeners. Join hosts Bethany Brookshire and Rachelle Saunders as we talk through the show's history, how we've grown and changed, and what we love about the Science for the People. Here's to 500 more episodes!